Invivo Partners

EVENT: Today, Laura Rodríguez Gallego participated in the roundtable organized by ITEMAS on "The Role of Institutions in Participated Companies", alongside Ana Rodríguez Cala, Rafael Mañez Mendiluce, and Yolanda Puiggròs Jiménez de Anta, moderated by Lluís Blanch and Ramon Maspons Bosch.

EVENTS: Yesterday, Laura Rodríguez Gallego participated as a panelist in an insightful discussion on "Innovative Funding Mechanisms and Business Models in Orphan and Rare Diseases," moderated by Daria Julkowska, Scientific Coordinator at the European Joint Programme on Rare Diseases. Joining her on the panel were industry leaders Catriona Crombie, Head of Rare Diseases at LifeArc, and James Levine, President of Foundation Ipsen. They explored how innovative funding approaches can accelerate progress in rare disease treatment, focusing on challenges and opportunities, alternative funding mechanisms, and the crucial role of patient associations.

PORTFOLIO NEWS: We’re thrilled to share a major milestone from our portfolio company, ARTHEx Biotech! The first patient has been dosed in their Phase I-IIa ArthemiR™ trial, testing ATX-01 for Myotonic Dystrophy Type 1 (DM1). This groundbreaking therapy is the first anti-microRNA treatment targeting DM1, aiming to address a critical unmet medical need in this rare and debilitating disease. This achievement underscores the dedication of the ARTHEx team as they continue to pioneer cutting-edge therapies that could transform the treatment landscape for DM1 and offer new hope to those affected by this rare condition.

📢📢 Job Opportunity: Senior Grants and Project Manager at #OneChainImmunotherapeutics We're looking for an experienced and highly-motivated Grants and Project Manager with a background in pre-, and post-award management within the life sciences sector to manage the complete grant process. Located in Parc Científic de Barcelona, we offer a competitive salary, a team-focused environment, and the chance to contribute to groundbreaking research. Ideal candidates will have: 🔴 BSc or MSc in life sciences, but a PhD is preferrable. 🔴 A minimum of 5 years’ experience in a grants application and management role within a university, research institution, pharma or biotech, in a life science focused environment. 🔴 Specific experience managing EIC and/or other Horizon Europe grants (required). 🔴 Fluency in Spanish and English, as a minimum. 📅 Apply by sending your CV, a cover letter and two referee e-mails to the CEO, Stefanos Theoharis. Applications should be sent to the CEO, Stefanos Theoharis (stefanos@onechaintx.com) before November 15th, 2024. Include "Senior Grants Manager - your_name" in the subject line. Check the full offer here👇

We are pleased to have our science recognized by Science Advances, which highlights the dual mechanism of our AntimiR technology and demonstrates the promising potential of RNA therapeutics in addressing the underlying disease-driving mechanisms of DM1. Learn more here:https://lnkd.in/gWptNP_g #RNAInnovation #MicroRNA #Biotech #MyotonicDystrophy #DM1

EVENTS: Today, Borja Ruiz Martínez, analyst at Invivo Partners, is attending Startup DeepTech Bootcamp 2024 by ACCIÓ where he is meeting innovative startups in the deeptech sector. The event is taking place at Club Natació Barcelona, Hospitality for the 37th America's Cup, where attendees also have the opportunity to enjoy the event.

Tomorrow, Laura Rodríguez Gallego will participate in an exciting roundtable discussion at the Alcura Summit 2024, exploring the challenges and opportunities in the CGT landscape alongside a diverse panel of professionals in the field.

Engaging discussion on the challenges, emerging trends, and key value drivers shaping the Cell & Gene Therapy (C&GT) space, as well as the potential growth opportunities in Europe at Advanced Therapies Europe 2024. At Invivo Partners, we’re confident that the C&GT field will continue to advance, with promising expansions into new indications, the exploration of novel cell types, and the development of cutting-edge technologies to tackle the challenges ahead. #ATE24

EVENTS: Tomorrow, Laura Rodríguez Gallego, Partner at Invivo Partners participates at the round table Funding the ATMP Journey - From Seed to Commercial Success Assessing Risk Tolerance, Capital Expenditure And Allocation Strategies with Stefanos Theoharis, Giovanni Rizzo, Ilya Yasny and Chris Barkey at Advanced Therapies Europe 2024. #ATE24

PORTFOLIO NEWS: We are excited to announce that our portfolio company, Integra Therapeutics, has secured up to 10.5M€ from the European Commission. This funding, through the #EICAccelerator program, will support the development of their gene writing platform #FICAT. Congratulations to the whole team for this significant achievement!